Is Bariatric Surgery at Risk of Becoming Obsolete?
With the advent of GLP-1 analogs, does bariatric surgery have a future role in helping people lose weight? Medscape Medical News
ADA Advises Against Using Compounded GLP-1 RA Medications
In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of safety issues. Medscape Medical News
Curbing plastics pollution could help reduce global burden of breast cancer, analysis suggests
A new study suggests addressing plastic pollution could play a critical role not only in protecting the environment, but also in lowering breast cancer rates, which have been increasing globally, especially in younger adults.
Olema in deal with Novartis on Kisqali breast cancer combo collaboration
Post Content This post firse appeared on Healthcare Articles on Seeking Alpha. Want to know more? Read More
Ozempic and other weight loss drugs could be making people drink less, study says
Another study suggests that weight-loss meds like Wegovy (NVO) and Mounjaro (LLY) can help people cut back on drinking alcohol.Read more…
Is 1-Week Radiotherapy Safe for Breast Cancer?
A new study found that 1-week ultrahypofractionated radiotherapy regimen for breast cancer was associated with acceptable late toxicities at 1 year. Medscape Medical News
Belly Fat Beats BMI in Predicting Colorectal Cancer Risk
Central obesity demonstrated a stronger association with colorectal cancer risk than general obesity measured using body mass index, according to a large UK cohort study. Medscape Medical News
ASH 2024: New Leukemia Txs, Fewer Blood Clots With GLP-1 Rxs
On tap at ASH this year: Presentations on improved therapies for ALL and CLL and reduced blood clots with weight loss drugs. Medscape Medical News
Tirzepatide Officially Puts GLP-1 Meds on the Map for Obesity-Related Heart Failure
(MedPage Today) — CHICAGO — A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying heart failure with preserved ejection fraction (HFpEF), according to the SUMMIT trial.
Incident…
Why some people don’t lose weight with Wegovy
Clinical trials have shown that people using weight-loss jabs, such as Wegovy and Mounjaro, lose anywhere between 16% and 21% of their body weight. But the drugs don’t work for everyone.